Scientific program
Dear Colleagues, Dear Authors
We have received lots of requests, if there is any embargo introduced from the organizers' side in relation to communication on the scientific program and publication of the 13th C1-inhibitor Deficiency & Angioedema Workshop via your channels. As the Scientific Program is being finalized right now, authors and companies are entitled and authorized to make announcements related to their talks from the 13th of April 2023 an onwards. Nevertheless, publishing the abstract prior to the date of the meeting should be avoided. Thank you for your attention.
| Thursday, 4 May 2023 | |
| 13:00-20:00 | Registration |
| 17:00-17:30 | Welcome coffee |
| 17:30-19:05 | Opening ceremony |
| Welcome of the Guests | |
| Surprise performance | |
| Presentation "For HAE Patients" Award, Award Ceremony | |
| 19:05-20:05 | Opening lectures Chairs: Bruce Zuraw, Michael Kirschfink |
| I-01 | Lactoferrin - the alarmin which knows when is a time to kill and a time to heal Vladimir Leksa |
| I-02 | HAE with the plasminogen gene mutation K330E and other types of hereditary angioedema with normal C1-INH Konrad Bork |
| 20:05-22:05 | Welcome reception |
| Friday, 5 May 2023 | |
| 08:00-10:00 | Scientific Session I. Chairs: Anete Grumach, Tomaš Freiberger |
| 08:00-08:15 O-01 |
The Bradykinin cascade is activated in patients with Alzheimer’s disease and is activated in vitro by aggregated Aβ protein Allen Kaplan |
| 08:15-08:30 O-02 |
C1 inhibitor deficiency is associated with a procoagulant phenotype in both humans and mice Steven Grover |
| 08:30-08:45 O-03 |
Th2 predominance and decreased NK cells in patients with hereditary angioedema – a connection with autoimmune disease? Linda Sundler Björkman |
| 08:45-09:00 O-04 |
Determining the effects of Moringa Oleifera on hepatic and monocytic cell lines in C1 esterase inhibitor production Martin Gonzo |
| 09:00-09:15 O-05 |
Purification and characterization of the C1 inhibitor R444C variant causing type 2 hereditary angioedema; covalent binding to human serum albumin and consequences József Dobó |
| 09:15-09:30 O-06 |
Cell-cell contacts and the glycocalyx are relevant structures in bradykinin-mediated endothelial barrier injury Robin Lochbaum |
| 09:30-09:45 O-07 |
Monocytes hyperactivity and endothelial dysfunction in hereditary angioedema: the MONOBRAD Study Nicolas Ozanne |
| 09:45-10:00 O-08 |
Biological pathway analyses of plasma proteomics in hereditary angioedema due to C1 inhibitor deficiency following lanadelumab treatment Dan Sexton |
| 10:00-10:30 | Coffee break |
| 10:30-12:10 | Scientific Session II. Chairs: Teresa Caballero, Avner Reshef |
| 10:30-10:50 O-09 |
An updated and comprehensive classification and terminology of angioedema Avner Reshef |
| 10:50-11:05 O-10 |
Detection of Bradykinin and its major metabolites by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) Huamin Henry Li |
| 11:05-11:20 O-11 |
Diagnosis of angioedema by Artificial Intelligence Felix Aulenbacher |
| 11:20-11:35 O-12 |
SERPING1 splicing-affecting variants highly represented in the Czech cohort of HAE-1/HAE-2 patients Tomas Freiberger |
| 11:35-11:50 O-13 |
HAErmony-1: Clinical study of adeno associated virus vector-mediated gene therapy of human C1-inhibitor in Hereditary Angioedema Type I and II Marc Riedl |
| 11:50-12:10 | Pregnancy consensus moderated by Teresa Caballero |
| 12:10-13:10 | Lunch break |
| 13:10-14:10 | Scientific Session III. Chairs: Anastasios Germenis, Despina Sanoudou, Matija Rijavec |
| 13:10-13:30 I-03 |
CRISPR opens the way to genetic therapy of angioedema Despina Sanoudou |
| 13:30-13:45 O-14 |
Hereditary angioedema variant curation using a ClinGen framework Matija Rijavec |
| 13:45-14:00 | International consensus on the use of genetics in the management of hereditary angioedema – The 2023 revision and update Round table discussion and voting by Anastasios Germenis |
| 14:00-16:00 | Poster session I. with coffee Chairs: Timothy Craig, Sandra Christiansen, Markus Magerl |
| P-01 | One-year epidemiologic data from Angioedema Center Vienna, Austria Tamar Kinaciyan |
| P-02 | Outcome parameters to measure efficacy of prophylactic therapy for hereditary angioedema: a systematic review Remy Petersen |
| P-03 | Efficacy and safety of Lanadelumab in Russian participants with hereditary angioedema (HAE) Elena Latysheva |
| P-04 | Mimics of hereditary angioedema in an emergency department Marko Barešić |
| P-05 | Mechanistic modeling and simulations predict long-term HAE attack prevention with STAR-0215 Jou-Ku Chung |
| P-06 | The impact of dental procedures on angioedema attacks – An observational study of patients enrolled in the Romanian Hereditary Angioedema Registry Valentin Nadasan |
| P-07 | The analysis of the effect of the COVID-19 pandemic on C1-inhibitor deficient hereditary angioedema patients Dávid Szilágyi |
| P-08 | Clinical spectrum of high titre anti-Ro/SSA antibodies in patients with hereditary angioedema with C1 inhibitor deficiency Sladjana Andrejevic |
| P-09 | Efficacy and safety of rituximab in angioedema with acquired C1 inhibitor deficiency Galith Kalmi |
| P-10 | Hereditary angioedema in the Republic of Panama Olga M. Barrera |
| P-11 | Vascular neural control blockade in a COVID-19 positive hereditary angioedema patient Francesca Perego |
| P-12 | A value-based and human centred innovative approach based on persona: Psychosocial needs of hereditary angioedema patients and caregivers Francesca Perego |
| P-13 | Decreased adhesion to the endothelium leads to elevated neutrophil granulocyte count in hereditary angioedema patients Erika Kajdácsi |
| P-14 | Psychodynamic factors impacting the degree of trust in the relationship between a doctor and a HAE patient Ekaterina A. Viktorova |
| P-15 | Targeted sequencing panel for the diagnosis of hereditary angioedema due to C1 inhibitor deficiency Matija Rijavec |
| P-16 | Route of administration preferences of people with hereditary angioedema for on-demand treatment: A US-based qualitative study Laurence Boulliet |
| P-17 | Second patient with kininogen 1 mutation in hereditary angioedema Gaëlle Hardy |
| P-18 | A retrospective study (INTEGRATED) of real-world effectiveness of Lanadelumab in European patients with HAE Type I/II Markus Magerl |
| P-19 | Quality of life in patients with hereditary angioedema in Latvia
Kanepa Adine |
| P-20 | Burden of hereditary angioedema type I and II: Preliminary results from a real-world study in Europe, Israel and Canada Henriette Farkas |
| P-21 | Assisted reproductive techniques in patients with Bradykinin-induced angioedema
Tatiana Navarro-Cascales |
| P-22 | Prevalence of non-alcoholic steatohepatitis in adult patients with hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH) Teresa Caballero |
| P-23 | Possible psychological fluctuations in severity and frequency of hereditary angioedema swellings Tomaz Garcez |
| P-24 | Real-life experience after eight months of long-term subcutaneous C1-inhibitor prophylactic treatment in four Hungarian patients with hereditary angioedema due to C1-inhibitor deficiency Hanga Réka Horváth |
| P-25 | Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist PHVS416 in patients with hereditary angioedema attacks Marc A. Riedl |
| 16:30- | Social program outside with discussion |
| Saturday, 6 May 2023 | |
| 08:00-09:30 | Scientific Session IV. Chairs: Hilary Longhurst, Isabelle Boccon-Gibod |
| 08:00-08:15 O-15 |
Attack-free status across subgroups of patients with hereditary angioedema (HAE) after 96 weeks of berotralstat treatment: results from the APeX-S trial Avner Reshef |
| 08:15-08:30 O-16 |
Rationale for the short-term prophylaxis regimen with Sebetralstat in KONFIDENT-S Michael Smith |
| 08:30-08:45 O-17 |
One-year results from an open-label study of Donidalorsen in patients with hereditary angioedema Laura Bordone |
| 08:45-09:00 O-18 |
The EC85 derived from the oral bradykinin B2 receptor antagonist PHA121 against bradykinin effects in healthy volunteers predicts the onset and duration of its clinical effects in hereditary angioedema Marcus Maurer |
| 09:00-09:15 O-19 |
Efficacy and safety of the oral bradykinin B2 receptor antagonist PHVS416 in treatment of hereditary angioedema attacks: topline results of RAPIDe-1 phase 2 trial Henriette Farkas |
| 09:15-09:30 O-20 |
Design of ALPHA-STAR, a Phase 1b/2 proof-of-concept trial of STAR-0215 as a long-active preventative therapy in patients with hereditary angioedema (HAE) Types I or II Marcus Maurer |
| 09:30-10:00 | Coffee break |
10:00-11:15 | Scientific Session V. Chairs: Connie Katelaris, Marcus Maurer |
| 10:00-10:15 O-21 |
Transient exposure to NTLA-2002, an investigational CRISPR/Cas9-based gene editing therapy, leads to durable pharmacodynamic responses and attack control in patients with hereditary angioedema Hilary Longhurst |
| 10:15-10:30 O-22 |
Prototype of a mobile application to record prodromes and attacks of hereditary angioedema Iris Leibovich-Nassi |
| 10:30-10:45 O-23 |
Garadacimab for hereditary angioedema prophylaxis: Long-term efficacy and safety from the VANGUARD Phase 3b open-label extension trial (first interim analysis) Avner Reshef |
| 10:45-11:00 O-24 |
Effect of prophylactic immunomodulation in non-human primates treated with BMN 331, an AAV5 gene therapy for hereditary angioedema Benjamin M. Hock |
| 11:00-11:15 O-25 |
Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial Timothy J. Craig |
| 11:15-11:45 | Coffee break |
| 11:45-13:00 | Scientific Session VI. Chairs: Konrad Bork, Laurence Bouillet |
| 11:45-12:00 O-26 |
Prophylaxis of angioedema attacks due to acquired C1-Inhibitor deficiency with PHA121, a novel oral bradykinin B2 receptor antagonist Remy S. Petersen |
| 12:00-12:15 O-27 |
Patient case series of hereditary angioedema with normal C1 inhibitor and factor XII mutation: Findings from an Allergy and Immunology Department in Argentina Ricardo D. Zwiener |
| 12:15-12:30 O-28 |
Characteristics of acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH) at a large tertiary care hospital in Spain Patricia Mir Ihara |
| 12:30-12:45 O-29 |
Angioedema due to acquired C1-inhibitor deficiency associated to monoclonal gammopathies of undetermined significance - Characteristics of a French national cohort Delphine Gobert |
| 12:45-13:00 O-30 |
A novel diagnostic parameter for acquired C1-inhibitor deficiency Zsófia Godnic-Pólai |
| 13:00-14:00 | Lunch break |
| 14:00-15:30 | Scientific Session VII. Chairs: Huamin Henry Li, Miloš Ješenak |
| 14:00-14:15 O-31 |
Long-term prophylaxis with Lanadelumab for children and adolescents with HAE Ekaterina A. Viktorova |
| 14:15-14:30 O-32 |
Is pre-procedural prophylaxis needed in patients receiving the newer HAE-C1INH prophylactic therapies? Teresa Caballero |
| 14:30-14:45 O-33 |
Quality of life, disease control and mental health in patients with hereditary angioedema in Slovakia – national online survey Milos Jesenak |
| 14:45-15:00 O-34 |
Effectiveness of an adapted treatment schedule for long-term prophylaxis in patients with HAE-C1-INH Johana Gil-Serrano |
| 15:00-15:15 O-35 |
Lanadelumab effectiveness and safety regardless of dosing and dosing changes in patients with hereditary angioedema from the United States and Canada: Real-world evidence from the EMPOWER Study Stephen D. Betschel |
| 15:15-15:30 O-36 |
HAE patients decision to carry on-demand treatment when away from home Stephen Betschel |
| 15:30-16:00 | Coffee break |
| 16:00-18:00 | Poster session II. Chairs: Peter Spӓth, Emel Aygören-Pürsün, Mauro Cancian |
| P-26 | Evolution of health-related quality of life in patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) and its relationship with disease activity Ines Fernandez-Concha Llona |
| P-27 | Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist PHA-022121 Brigitte Loenders |
| P-28 | Recombinant human C1 esterase inhibitor on-demand treatment for attacks of hereditary angioedema: A European registry update Anna Valerieva |
| P-30 | Genetic segregation study in hereditary angioedema with normal C1-inhibitor due to F12 mutation in Southern Spanish population - an observational study Krasimira Baynova |
| P-31 | Case report: Off-label long-term prophylaxis with C1-esterase-inhibitor (C1-INH) s.c. in a patient with acquired C1-INH-deficiency (C1-INH-AAE) Eva-Vanessa Ebert |
| P-32 | Specific anti-spike IgG subclasses in patients with C1-INH-HAE (C1-esterase inhibitor deficiency hereditary angioedema) after different types of COVID-19 vaccines Petra Kiszel |
| P-33 | Patients with hereditary angioedema comply with regular immunization? Pilot study Anete Grumach |
| P-34 | C1-INH complexes as markers for classical and lectin pathway activation and complex levels in angioedema patients Lisa Hurler |
| P-35 | Organization and patient activity Elena Bezbozhnaya |
| P-36 | Hereditary angioedema with normal C1 inbibitor and cutis laxa: An unusual association Regis Campos |
| P-37 | Development of HAE awareness in the Czech Republic Camelia Isaic |
| P-38 | Efficacy of the oral bradykinin B2 receptor antagonist PHVS416 by attack symptom in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks Anna Valerieva |
| P-39 | First report of FXII gene pathogenic variant in a Mexican family with hereditary angioedema Francisco Alberto Contreras |
| P-40 | Hereditary angioedema with a mutation in the plasminogen gene Signe Purina |
| P-41 | Experience in the use of pathogenetic therapy for arresting hereditary angioedema (HAE) attacks in pediatric patients Ekaterina A. Viktorova |
| P-42 | Prevailing swelling of the abdominal cavity, as an atypical course of HAE Liudmyla Zabrodska |
| P-43 | A patient who was diagnosed with hereditary angioedema at two different times Beáta Visy |
| P-44 | The patient journey: From mesenteric panniculitis and angioedema to acquired angioedema Ricardo Zwiener |
| P-45 | An uncommon case of postpartum venous thrombosis in a patient with C1INH-HAE Francesco Giardino |
| P-46 | A young woman with C1-INH deficiency refractory to various treatments: The relevance of having all therapeutic strategies available Beatrice Piazza |
| P-47 | Safety of COVID-19 vaccines in patients with angioedema with C1 inhibitor deficiency: Data from Italian Network for Hereditary and Acquired Angioedema (ITACA) Andrea Zanichelli |
| P-48 | Garadacimab for hereditary angioedema prophylaxis in adolescents: Efficacy and safety from the VANGUARD Phase 3 and 3b open-label extension trial (first interim analysis) Markus Magerl |
| P-49 | Transmission patterns in C1-INH deficiency hereditary angioedema favours a wild-type male offspring: Our experience at Chandigarh, India Ankur Jindal |
| P-50 | Profile of Hereditary Angioedema from Nepal- A speck of imprint on Everest Dharmagat Bhattarai |
| 18:30- | Social program outside with discussion |
| Sunday, 7 May 2023 | |
| 08:00-10:00 | Scientific Session VIII. Chairs: Sladjana Andrejevic, Danny Cohn |
| 08:00-08:15 O-37 |
The ACARE network – An update on global angioedema projects and initiatives Marcus Maurer |
| 08:15-08:30 O-38 |
The angioedema registry of the Italian Network for Hereditary and Acquired Angioedema (ITACA): a tool to monitor HAE course, therapeutic adherence and overall burden of the disease Mauro Cancian |
| 08:30-08:45 O-39 |
The impact of puberty on C1INH-HAE course: A survey from the Italian Network for Hereditary and Acquired Angioedema (ITACA) Riccardo Senter |
| 08:45-09:00 O-40 |
Comorbidities in angioedema due to C1-INH deficiency: A survey from the Italian Network for Hereditary and Acquired Angioedema (ITACA) Andrea Zanichelli |
| 09:00-09:15 O-41 |
Pharmacoeconomic burden for HAE patients in Brazil Marina Teixeira Henriques |
| 09:15-09:30 O-42 |
Management of hereditary angioedema with normal C1Inh: About a series of 149 French cases Laurence Bouillet |
| 09:30-09:45 O-43 |
Diagnostic criteria of angiotensin converting enzyme inhibitors (ACEi) induced bradykinin angioedema: The experience from the French national reference center for angioedema Alexis Bocquet |
| 09:45-10:00 O-44 |
Autoimmune disorders in C1INH-hereditary angioedema: Preliminary data of a prospective study from an ITACA cohort Mauro Cancian |
| 10:00-10:30 | Coffee break |
| 10:30-11:30 | Scientific Session IX. Chairs: Aharon Kessel, Andrea Zanichelli |
| 10:30-10:45 O-45 |
Health-related quality of life with garadacimab for hereditary angioedema prophylaxis: Results from a phase 2 trial Avner Reshef |
| 10:45-11:00 O-46 |
Quality of life in hereditary angioedema in Brazil: A multicentric study Lucca Nogueira Paes Jannuzzi |
| 11:00-11:15 O-47 |
Real-world effectiveness data on lanadelumab in HAE long term prophylaxis in Slovakia Anna Bobcakova |
| 11:15-11:30 O-48 |
Understanding the impact of HAE attacks on patient reported quality-of-life - analysis of real-world patient data David Hinds |
| 11:30-12:15 | Closing Ceremony |
| 11:30-12:00 | ’Grant for Young Investigators’ Ceremony performed by Stephen Betschel |
| 12:00-12:10 | Closing remarks performed by Allen Kaplan |
| 12:15-14:00 | Lunch |
| 14:00- | Departure |
